Howard Hochster, M.D.
USA

Howard Hochster, M.D. <br>USA

“My clinical expertise and research interests are dedicated to early drug development and clinical pharmacology, focused on tumors of the gastrointestinal tract. I have led numerous clinical trials and have been at the forefront of clinical research in GI Oncology and have been instrumental in the approval of eight new drugs for the treatment of colon cancer. Together with my SWOG and NCTN colleagues, we strive to design and conduct the studies that set standards of care for pioneering new treatments in cancer care”.

 

Howard Hochster, M.D., is the Associate Director for Clinical Research and Director, Gastrointestinal (GI) Oncology at Rutgers Cancer Institute New Jersey and Director of Oncology Research for RWJBarnabas Health. His clinical expertise and research interests are dedicated to early drug development and clinical pharmacology, focused on tumors of the gastrointestinal tract. He has authored more than 150 peer-reviewed articles on cancer therapy, new drug development and clinical trials and chaired the GI Cancer Committee for SWOG since 2013. He is also closely involved with the NCI National Clinical Trials Network (NCTN) and has chaired ten phase 2 and phase 3 studies in the NCI cooperative groups. He is also Medical Director of the Chemotherapy Foundation. He has authored more than 150 peer-reviewed articles on cancer therapy, new drug development and clinical trials and presented many of these study results at national meetings.

 

Back to International external experts